Vistagen Therapeutics

Vistagen Therapeutics VTGN Stock

$0.20   6.117020%
Add to favorites
Market Cap
$9.21M
LOW - HIGH [24H]
$0.18 - $0.20
VOLUME [24H]
$1.03M
P/E Ratio
0
Earnings per share
-$1.36
ISIN
US92840H4002
Price   Prediction

Vistagen Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Vistagen Therapeutics (VTGN) stock price today is 0.2 USD on Tech Market Small (+6.12% on the day). Updated .

Vistagen Therapeutics VTGN Financial and Trading Overview

Vistagen Therapeutics stock price 0.2 USD
Previous Close 0.19 USD
Open 0.19 USD
Bid 0.18 USD x 100
Ask 0.38 USD x 200
Day's Range 0.18 - 0.2 USD
52 Week Range 0.16 - 5.14 USD
Volume 994.42K USD
Avg. Volume 10.28M USD
Market Cap 9.21M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -1.36 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 1 USD

VTGN Valuation Measures

Enterprise Value -10741023 USD
Trailing P/E N/A
Forward P/E -0.12954545
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 3.8698514
Price/Book (mrq) 0.60638297
Enterprise Value/Revenue -4.511
Enterprise Value/EBITDA 0.178

Trading Information

Vistagen Therapeutics Stock Price History

Beta (5Y Monthly) N/A
52-Week Change -95.77%
S&P500 52-Week Change 10.51%
52 Week High 5.14 USD
52 Week Low 0.16 USD
50-Day Moving Average 0.22 USD
200-Day Moving Average 0.42 USD

VTGN Share Statistics

Avg. Volume (3 month) 10.28M USD
Avg. Daily Volume (10-Days) 755.4K USD
Shares Outstanding 46.19M
Float 43.11M
Short Ratio 2.47
% Held by Insiders 0.35%
% Held by Institutions 26.83%
Shares Short 2.49M
Short % of Float 5.48%
Short % of Shares Outstanding 5.45%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor 1:30

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 0%
Operating Margin (ttm) -2543.13%
Gross Margin 100.00%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -72.53%
Return on Equity (ttm) -144.94%

Income Statement

Revenue (ttm) 2.38M USD
Revenue Per Share (ttm) 0.06 USD
Quarterly Revenue Growth (yoy) -46.50%
Gross Profit (ttm) 2.38M USD
EBITDA -60344000 USD
Net Income Avi to Common (ttm) -58943000 USD
Diluted EPS (ttm) -1.36
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 20.03M USD
Total Cash Per Share (mrq) 0.43 USD
Total Debt (mrq) 610K USD
Total Debt/Equity (mrq) 4.07 USD
Current Ratio (mrq) 2.645
Book Value Per Share (mrq) 0.329

Cash Flow Statement

Operating Cash Flow (ttm) -60701000 USD
Levered Free Cash Flow (ttm) -38176000 USD

Profile of Vistagen Therapeutics

Country United States
State CA
City South San Francisco
Address 343 Allerton Avenue
ZIP 94080
Phone 650 577 3600
Website https://www.vistagen.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 41

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Q&A For Vistagen Therapeutics Stock

What is a current VTGN stock price?

Vistagen Therapeutics VTGN stock price today per share is 0.2 USD.

How to purchase Vistagen Therapeutics stock?

You can buy VTGN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Vistagen Therapeutics?

The stock symbol or ticker of Vistagen Therapeutics is VTGN.

Which industry does the Vistagen Therapeutics company belong to?

The Vistagen Therapeutics industry is Biotechnology.

How many shares does Vistagen Therapeutics have in circulation?

The max supply of Vistagen Therapeutics shares is 46.19M.

What is Vistagen Therapeutics Price to Earnings Ratio (PE Ratio)?

Vistagen Therapeutics PE Ratio is now.

What was Vistagen Therapeutics earnings per share over the trailing 12 months (TTM)?

Vistagen Therapeutics EPS is -1.36 USD over the trailing 12 months.

Which sector does the Vistagen Therapeutics company belong to?

The Vistagen Therapeutics sector is Healthcare.

Vistagen Therapeutics VTGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us US Tech Industrial INDS US 13012.51 USD —
+1.14
— — 12881.24 USD — 13074.17 USD — — — —
us US Tech Capital Market Composite RCMP US 108.78 USD —
+0.08
— — 108.35 USD — 109.95 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
$2.17T
Total marketcap
$73.12B
Total volume
BTC 58.89%   •   ETH 10.14%
Dominance
Select currency